BACKGROUND: How platelet (PLT) product characteristics such as dose, source (whole blood derived [WBD] vs. apheresis), storage duration, and ABO matching status affect the risks of transfusion-related adverse events (TRAEs) is unclear. Similarly, more information is needed to define how recipient characteristics affect the frequency of TRAEs after PLT transfusion. STUDY DESIGN AND METHODS: In the multicenter Platelet Dose ("PLADO") study, pediatric and adult hematology-oncology patients with hypoproliferative thrombocytopenia were randomized to receive low-dose (LD), medium-dose (MD), or high-dose (HD) PLT prophylaxis for a pretransfusion PLT count of not more than 10 × 10(9) /L. All PLT units (apheresis or WBD) were leukoreduced. Post hoc analyses of PLADO data were performed using multipredictor models. RESULTS:A total of 5034 PLT transfusions to 1102 patients were analyzed. A TRAE occurred with 501 PLT transfusions (10.0%). The most common TRAEs were fever (6.6% of transfusions), allergic or hypersensitivity reactions (1.9%), and sinus tachycardia (1.8%). Patients assigned HD PLTs were more likely than LD or MD patients to experience any TRAE (odds ratio for HD vs. MD, 1.50; 95% confidence interval, 1.10-2.05; three-group comparison p = 0.02). PLT source and ABO matching status were not significantly related to overall TRAE risk. Compared to a patient's first PLT transfusion, subsequent PLT transfusions were less likely to have a TRAE reported, primarily due to a lower risk of allergic or hypersensitivity reactions. CONCLUSION: The most important PLT unit characteristic associated with TRAEs was PLT dose per transfusion. HD PLTs may increase the risk of TRAEs, and LD PLTs may reduce the risk.
RCT Entities:
BACKGROUND: How platelet (PLT) product characteristics such as dose, source (whole blood derived [WBD] vs. apheresis), storage duration, and ABO matching status affect the risks of transfusion-related adverse events (TRAEs) is unclear. Similarly, more information is needed to define how recipient characteristics affect the frequency of TRAEs after PLT transfusion. STUDY DESIGN AND METHODS: In the multicenter Platelet Dose ("PLADO") study, pediatric and adult hematology-oncology patients with hypoproliferative thrombocytopenia were randomized to receive low-dose (LD), medium-dose (MD), or high-dose (HD) PLT prophylaxis for a pretransfusion PLT count of not more than 10 × 10(9) /L. All PLT units (apheresis or WBD) were leukoreduced. Post hoc analyses of PLADO data were performed using multipredictor models. RESULTS: A total of 5034 PLT transfusions to 1102 patients were analyzed. A TRAE occurred with 501 PLT transfusions (10.0%). The most common TRAEs were fever (6.6% of transfusions), allergic or hypersensitivity reactions (1.9%), and sinus tachycardia (1.8%). Patients assigned HD PLTs were more likely than LD or MD patients to experience any TRAE (odds ratio for HD vs. MD, 1.50; 95% confidence interval, 1.10-2.05; three-group comparison p = 0.02). PLT source and ABO matching status were not significantly related to overall TRAE risk. Compared to a patient's first PLT transfusion, subsequent PLT transfusions were less likely to have a TRAE reported, primarily due to a lower risk of allergic or hypersensitivity reactions. CONCLUSION: The most important PLT unit characteristic associated with TRAEs was PLT dose per transfusion. HD PLTs may increase the risk of TRAEs, and LD PLTs may reduce the risk.
Authors: William J Savage; Robert G Hamilton; Aaron A R Tobian; Ginger L Milne; Richard M Kaufman; Jessica H Savage; P Dayand Borge; Paul M Ness Journal: J Allergy Clin Immunol Date: 2014-05-01 Impact factor: 10.793
Authors: William J Savage; Aaron A Tobian; Alice K Fuller; Robert A Wood; Karen E King; Paul M Ness Journal: Transfusion Date: 2011-01-07 Impact factor: 3.157
Authors: Darrell J Triulzi; Susan F Assmann; Ronald G Strauss; P M Ness; John R Hess; Richard M Kaufman; Suzanne Granger; Sherrill J Slichter Journal: Blood Date: 2012-04-10 Impact factor: 22.113
Authors: Sherrill J Slichter; Richard M Kaufman; Susan F Assmann; Jeffrey McCullough; Darrell J Triulzi; Ronald G Strauss; Terry B Gernsheimer; Paul M Ness; Mark E Brecher; Cassandra D Josephson; Barbara A Konkle; Robert D Woodson; Thomas L Ortel; Christopher D Hillyer; Donna L Skerrett; Keith R McCrae; Steven R Sloan; Lynne Uhl; James N George; Victor M Aquino; Catherine S Manno; Janice G McFarland; John R Hess; Cindy Leissinger; Suzanne Granger Journal: N Engl J Med Date: 2010-02-18 Impact factor: 91.245
Authors: Katherine D Ellingson; Mathew R P Sapiano; Kathryn A Haass; Alexandra A Savinkina; Misha L Baker; Koo-Whang Chung; Richard A Henry; James J Berger; Matthew J Kuehnert; Sridhar V Basavaraju Journal: Transfusion Date: 2017-06 Impact factor: 3.157
Authors: Ana Isabel Pérez Aliaga; Gorka Labata; Alfonso Aranda; Marcia Cardoso; Fernando Puente; José María Domingo; Carmen Garcés Journal: Transfus Med Hemother Date: 2021-06-09 Impact factor: 3.747
Authors: Emily Crawford; Jack Kamm; Steve Miller; Lucy M Li; Saharai Caldera; Amy Lyden; Deborah Yokoe; Amy Nichols; Nam K Tran; Sarah E Barnard; Peter M Conner; Ashok Nambiar; Matt S Zinter; Morvarid Moayeri; Paula Hayakawa Serpa; Brian C Prince; Jenai Quan; Rene Sit; Michelle Tan; Maira Phelps; Joseph L Derisi; Cristina M Tato; Charles Langelier Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Olivier Garraud; S Tariket; C Sut; A Haddad; C Aloui; T Chakroun; S Laradi; F Cognasse Journal: Front Immunol Date: 2016-11-29 Impact factor: 7.561